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Abstract
Background: Oncoprotein HCCR-1 functions as a negative regulator of the p53 and contributes
breast tumorigenesis. The serum HCCR-1 assay is useful in diagnosing breast cancer and mice
transgenic for HCCR developed breast cancers. But it is unknown how HCCR-1 contributes to
human breast tumorigenesis.
Methods: Oncogene HCCR-1 expression levels were determined in normal breast tissues, breast
cancer tissues and cancer cell lines. We examined whether HCCR-1 protein expression in breast
cancer is related to different biological characteristics, including ER, PR, p53 genotype, and HER2
status in 104 primary breast cancer tissues using immunohistochemical analyses.
Results: HCCR-1 was upregulated in breast cancer cells and tissues compared with normal breast
tissues. In this study, overexpression of HCCR-1 was well correlated with known breast cancer
prognostic markers including the presence of steroid receptors (ER and PR), p53 mutation and high
HER2 overexpression. HCCR-1 was not detected in the ER-negative, PR-negative, p53 negative and
low HER2 breast cancer tissues. These data indicate that the level of HCCR-1 in breast cancer
tissues is relatively well correlated with known breast cancer factors, including the HER2
overexpression, p53 mutation, and ER/PR status.
Conclusion: Determination of HCCR-1 levels as options for HER2 testing is promising although
it needs further evaluation.
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Introduction
Cells expressing HCCR-1 are tumorigenic in nude mice
[1]. The functional role of this oncogene in tumorigenesis
is manifested as a negative regulator of the p53 tumor sup-
pressor [1]. In the previous study, we investigated HCCR-
1 protein expression in breast cancer and the possibility of
using HCCR-1 as a useful biomarker for human breast
cancer [2]. We also examined whether HCCR-1 protein
expression in breast cancer is related to different biologi-
cal characteristics including ER, PR, p53 genotype, and the
HER2 status. Northern and Western blot analyses and
immunohistochemical studies indicate that the HCCR-1
mRNA and protein are overexpressed in breast cancer tis-
sues compared to the normal breast tissues [1,2]. Serolog-
ical studies revealed an 86.8% sensitivity for HCCR-1 in
breast cancer, which was higher than 21.0% for CA15-3
[2,3]. The HCCR-1 assay has an advantage over CA15-3 in
diagnosing breast cancer. These results indicate that
HCCR-1 is an oncoprotein that is related to breast cancer
development [1,2].
Overexpression of human epidermal growth factor recep-
tor type 2 (HER2, also referred to as HER2/neu or ErbB-2),
a 185-kD receptor first described more than two decades
ago [4], occurs in 20 to 30% of invasive breast cancers. In
general, patients with breast-cancer cells that overexpress
this receptor or that have a high copy number of its gene
have decreased overall survival and may have differential
responses to a variety of chemotherapeutic and hormonal
agents [5,6]. Thus, strategies to target HER2 appear to be
important in treating breast cancer [7]. HER2 signaling
promotes cell proliferation through the RAS-MAPK path-
way and inhibits cell death through the phosphatidyli-
nositol 3'-kinase-AKT-mammalian target of rapamycin
(mTOR) pathway [8]. Likewise, the HCCR-1 signaling is
also known to be regulated by the phosphatidylinositol
3'-kinase-AKT pathway [9].
According to our previous study using a panel of breast
cancer cell lines [2], HCCR-1 was highly expressed in
breast cancer cell lines with high HER2 overexpression,
with some exceptions, that have a mutated p53 and
express ER/PR [10-13]. These data indicate that the
HCCR-1 overexpression in breast cancer cell lines is well
correlated with known breast cancer prognostic markers
including high HER2 overexpression [10-13].
Because HER2 overexpression and amplification have
important consequences on the prognosis and treatment
of breast cancer, their presence must be accurately deter-
mined. Currently, two different methods are being used
worldwide, immunohistochemistry (IHC) and fluores-
cence in situ hybridization (FISH). These two techniques
identify different targets and both have advantages and
disadvantages [14]. Which method should be viewed as
the gold standard for HER2 determination remains a
debate. Recently, other methods have been described as
options for HER2 testing. Real time polymerase chain
reaction (RT-PCR) [15] and chromogen in situ hybridiza-
tion (CISH) [16] have been proposed as cheaper and eas-
ier alternatives to FISH. Acceptable correlations between
both methods and FISH have been reported [14]. But the
correlations among the various clinical methods of detect-
ing HER2 are imperfect with regard to both prognostica-
tion and the prediction of a response to trastuzumab
(Herceptin, Genentech).
Multiple studies have demonstrated marked improve-
ment in disease-free and overall survival when trastuzu-
mab is incorporated in therapeutic regimens for HER2
overexpressed tumors [17,18]. Only patients whose
tumors strongly overexpress HER2 by immunohisto-
chemistry (IHC) and/or have amplification of the cerb2
gene by FISH, are likely to respond to Herceptin treatment
[19].
Testing invasive breast carcinomas for HER2 overexpres-
sion/gene amplification has become a standard of practice
[20]. Much of the recent literature has focused on the best
method for documenting HER2 overexpression (IHC vs.
FISH), technical limitations of each method, and the need
for consistency and QA in test performance [17,21-23].
The National Comprehensive Cancer Network HER2 Test-
ing in Breast Cancer Task Force concluded that where ade-
quate quality control/quality assurance procedures are
followed, either IHC or FISH are acceptable methods [24].
Whether a laboratory uses IHC with FISH for equivocal
cases, or uses FISH as the initial HER2 screen, these tests
are expensive to perform. Development of a rational
approach to selecting cases for HER2 testing would pro-
mote cost effectiveness in the health care system [25].
The aim of this study is to analyze the level of HCCR-1
expression in breast cancer tissues in order to demonstrate
its correlation to other biomarkers including ER, PR, p53,
and HER2, and estimate the possibility of HCCR-1 as a
new biomarker candidate for breast cancer.
Methods
Tissues and cell lines
Human normal and cancer tissues were obtained during
operation. All patients were subjected to the analysis with
individual consent for the study. The use of tissue samples
was approved by the Ethics Committee of our institution
(Kangnam St. Mary's Hospital, Seoul, Korea). Mammalian
cell lines were obtained from the American Type Culture
Collection (ATCC; Manassas, VA). BT-474, MCF-7 and
MDA-MB-231 are human breast carcinoma cell lines from
mammary gland. MCF7 and MDA-MB-231 cells expressBMC Cancer 2009, 9:51 http://www.biomedcentral.com/1471-2407/9/51
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low HER2, and BT-474 cells express high HER2. BT-474
and MCF-7 cells are ER-positive and PR-positive cells.
MDA-MB-231 is ER-negative and PR-negative cell line.
MCF-7 cells have wild type p53, and MDA-MB-231 and
BT-474 cells have mutated p53.
Northern blot analysis
Total RNA was extracted from fresh human tissues and cell
lines using RNeasy total RNA kit (Qiagen). Northern blot
analysis was carried out, in which 20 μg of denatured total
RNA was electrophoresed on a 1.0% formaldehyde agar-
ose gel and transferred to nylon membrane. Human β-
actin cDNA control probe was used as a loading control.
All blots were hybridized with the randomly primed [32P]-
labeled HCCR-1 partial cDNA probe.
Immunohistochemical analysis and staining interpretation
For immunohistochemistry experiments, paraffin sec-
tions (5-μm thick) of normal human breast and cancer tis-
sues were used for stainings using monoclonal antibodies
against ER, PR, and p53, and affinity-purified polyclonal
anti-HCCR-1 antibodies. Endogenous peroxide and non-
specific binding were blocked by using 3% hydrogen per-
oxide in TBST and with TBST diluted 1:10 in FBS for 30
minutes, respectively. Then sections were incubated with
primary antibodies (diluted in TBST-FBS solution) for 2
hours at room temperature. Corresponding negative con-
trols were incubated in the absence of primary antibody.
Aminoethyl carbozole (AEC) was used as the chromogen.
After immunostaining, sections were counterstained with
hematoxylin. Representative examples of stained tissues
were photographed under the microscope. Pathologist
counted at least 500 tumor cells in the area most strongly
stained for ER, PR and p53. Positive staining for ER, PR,
and p53 was defined by nuclear staining. According to
most accepted cut-off point, 10% positive staining of
tumor cells was used as positive result for ER, PR and p53.
Immunohistochemically detected p53 protein is mutated
p53 protein due to its prolonged half-life. The positive
staining of tumor cells is strongly correlated with p53
mutation [26]. The HER2 immunohistochemical staining
results were interpreted according to staining criteria. Pos-
itive staining for HER2 was defined by membrane stain-
ing. Cytoplasmic staining was not considered positive.
Tumor cells showing no immunoreactivity (score 0) or
the incomplete and faint membrane staining (score 1+)
were considered as negative. HER2 was defined as positive
when the complete weak to moderate membrane staining
(weakly positive; score 2+) or the complete strong mem-
brane staining (strongly positive; score 3+) was observed
in more than 10% of tumor cells. The HCCR-1 immuno-
histochemical staining results was defined by cytoplasmic
staining. The cut-off point of HCCR-1 for positive and
negative staining was used 0% of cells. We changed
HCCR-1 staining results as positive and negative results
instead of stability.
Results and discussion
Overexpression of HCCR-1 in breast cancers
We examined the expression patterns of HCCR-1  in
human normal tissues, cancer tissues and cell lines.
Northern blot analysis revealed an increased expression of
HCCR-1  in fresh primary human breast cancer tissues
compared to their normal counterparts (Fig. 1). HCCR-1
was abundantly detected in BT-474 (ER+/PR+/mutant
p53/HER2 3+) and MCF-7 (ER+/PR+/wild p53/HER2 -)
cells whereas it was not detected in MDA-MB-231 (ER-/
PR-/mutant p53/HER2 -) cells (Fig. 1). The expression
level of HCCR-1 was higher in BT-474 than in MCF-7.
HCCR-1 is well correlated with known breast cancer 
prognostic parameters
We conducted the following experiment to investigate
whether the results of our previous study in which breast
cancer cell lines were used [2] can be replicated in this
study using fresh primary breast cancer tissues. The
expression of HCCR-1 was measured in a panel of fresh
104 primary breast cancer tissues and their normal coun-
terparts (Table 1 and Fig. 2). The increasing expression
level of HCCR-1 was observed in the order of breast cancer
tissues with (ER+/PR+/mutant p53/HER 3+), (ER+/PR+/
wild p53/HER2 2+), and (ER+/PR+/wild p53/HER2 -).
HCCR-1 was not detected in breast cancer tissues with
(ER-/PR-/p53-/low HER2) (Table 1 and Fig. 2). These
results confirm our previous findings in breast cancer cell
lines in that HCCR-1 expression is correlated with known
prognostic markers for breast cancer.
Since HER2 overexpression/amplification has important
consequences on the prognosis and treatment of breast
HCCR-1 expressions in breast cancers Figure 1
HCCR-1 expressions in breast cancers. Northern analy-
ses of HCCR-1 in human breast tissues and cell lines. Com-
parison of HCCR-1 mRNA expressions in breast cancer cell 
lines (BT-474, MCF-7 and MDA-MB-231), and fresh primary 
breast cancer tissues (C) and their corresponding normal 
counterparts (N). Human β-actin cDNA was used as a con-
trol probe (bottom panel).BMC Cancer 2009, 9:51 http://www.biomedcentral.com/1471-2407/9/51
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Table 1: Correlation of the HCCR-1 expression levels in 104 primary breast cancer tissues with known breast cancer prognostic 
parameters including the ER/PR expression, p53 status and HER2 overexpression
No. of
Cancer tissues
ER
status
PR
status
p53
status
HER2
Over-expression
HCCR-1
expression
30 positive positive mutant strong positive positive
23 positive positive wild moderate positive positive
23 positive positive wild negative positive
28 negative negative null negative negative
All the breast cancer tissues were derived from pathologically-proven invasive ductal carcinomas.
cancer [10,13], its presence should be precisely deter-
mined. However, the various clinical methods of detect-
ing HER2 are not perfect with regard to both
prognostication and the prediction of a response to trastu-
zumab [14,27-29]. HER2 testing continues to evolve, and
many clinical laboratories currently use both tests (IHC
and FISH). An efficient testing strategy consists of immu-
nostaining followed by FISH in tumors with 2+ staining
intensity [29]. This approach should minimize the risks of
not treating patients who might benefit from trastuzumab
and of treating patients who are unlikely to have a
response; this is a critically important distinction as the
use of trastuzumab moves into the adjuvant setting [7].
Reported adjuvant trials used centralized laboratory
review because of the high rate of discordant interpreta-
tions among individual laboratories [30,31].
Our data reveal that the HCCR-1 expression is tightly
associated with HER2 activity in breast cancer tissues. This
implies that the prognosis for the breast cancer might be
improved when combining the measurement of the
HCCR-1 level and the HER2 activity.
Conclusion
Our results highlight the strong correlation of HCCR-1
expression in breast cancer to other prognostic factors and
HCCR-1 is positively well correlated with breast cancer prognostic parameters Figure 2
HCCR-1 is positively well correlated with breast cancer prognostic parameters. Correlation of HCCR-1 expres-
sion levels with known breast cancer prognostic parameters. Immunohistochemical staining for ER, PR, HER2, p53 and HCCR-
1 in fresh frozen tissues from human breast cancers. All the breast cancer tissues were derived from pathologically-proven 
invasive ductal carcinomas. Positive immunostaining for ER, PR, and p53 in the nuclei of carcinoma cells and for HCCR-1 in the 
cytoplasm of carcinoma cells (top panel). The HER2 immunohistochemical staining showing complete strong membrane stain-
ing (3+) in the carcinoma cells (top panel). Negative immunostaining for ER, PR, p53, HER2 and HCCR-1 in breast carcinoma 
(bottom panel). Original magnification, × 100.BMC Cancer 2009, 9:51 http://www.biomedcentral.com/1471-2407/9/51
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raise the possibility that HCCR-1 expression can be used
as a new prognostic marker for breast cancer.
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